Search
Avidity Biosciences Ord Shs
RNAMAdd to Watchlist
72.860
0.0000.00%
Close 04/17, 16:00（ET）Quotes delayed by 15 min
--Market Cap
--P/E TTM
More Details of Company
Avidity Biosciences Ord Shs Info
Ticker Symbol- -
Company name- -
IPO date- -
CEO- -
Number of employees- -
Security type- -
Fiscal year-end- -
Address- -
City- -
Stock exchange- -
Country- -
Postal code- -
Phone- -
Website- -
Ticker Symbol- -
IPO date- -
CEO- -
Company Executives of Avidity Biosciences Ord Shs
Name
Name/Position
Position
Shareholding
Change
Dr. Noreen Roth Henig, M.D.
Dr. Noreen Roth Henig, M.D.
Independent Director
Independent Director
--
--
Dr. Edward M. (Ed) Kaye, M.D.
Dr. Edward M. (Ed) Kaye, M.D.
Independent Director
Independent Director
--
--
Ms. Tamar Thompson
Ms. Tamar Thompson
Independent Director
Independent Director
--
--
Ms. Jean Kim
Ms. Jean Kim
Independent Director
Independent Director
--
--
Dr. W. Michael Flanagan, Ph.D.
Dr. W. Michael Flanagan, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Eric B. Mosbrooker
Mr. Eric B. Mosbrooker
Chief Commercial Officer
Chief Commercial Officer
--
--
Ms. Kathleen P. Gallagher
Ms. Kathleen P. Gallagher
Chief Program Officer
Chief Program Officer
--
--
Ms. Teresa Mccarthy
Ms. Teresa Mccarthy
Chief Human Resources Officer
Chief Human Resources Officer
--
--
Dr. Simona Skerjanec, M.D.
Dr. Simona Skerjanec, M.D.
Independent Director
Independent Director
--
--
Mr. John B. Moriarty
Mr. John B. Moriarty
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Noreen Roth Henig, M.D.
Dr. Noreen Roth Henig, M.D.
Independent Director
Independent Director
--
--
Dr. Edward M. (Ed) Kaye, M.D.
Dr. Edward M. (Ed) Kaye, M.D.
Independent Director
Independent Director
--
--
Ms. Tamar Thompson
Ms. Tamar Thompson
Independent Director
Independent Director
--
--
Ms. Jean Kim
Ms. Jean Kim
Independent Director
Independent Director
--
--
Dr. W. Michael Flanagan, Ph.D.
Dr. W. Michael Flanagan, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Eric B. Mosbrooker
Mr. Eric B. Mosbrooker
Chief Commercial Officer
Chief Commercial Officer
--
--
Revenue Breakdown
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2022
FY2021
FY2020
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Mar 9
Updated: Mon, Mar 9
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Hedge Fund
26.13%
Investment Advisor
25.74%
Investment Advisor/Hedge Fund
24.90%
Venture Capital
6.37%
Research Firm
4.47%
Corporation
3.27%
Sovereign Wealth Fund
1.98%
Private Equity
1.03%
Bank and Trust
0.69%
Other
5.41%
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Reporting Period
No. of institutions
Shares Held
Proportion
Change
No Data
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
No Data
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
